NCT00566761

Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Asociación para Evitar la Ceguera en México · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Detailed description

Comparison of two groups with different treatment with registrations of outcome in BCVA and complications

Conditions

• Macular Edema
• Central Retinal Vein Occlusion

Interventions

Type	Name	Description
DRUG	bevacizumab and triamcinolone	three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Timeline

• Start date: 2007-06-01
• Primary completion: 2007-06-01
• Completion: 2008-03-01
• First posted: 2007-12-04
• Last updated: 2024-05-30

Locations

1 site across 1 country: Mexico